Nemecek R - Search Results

1

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

Lupini L, Bassi C, Mlcochova J, Musa G, Russo M, Vychytilova-Faltejskova P, Svoboda M, Sabbioni S, Nemecek R, Slaby O, Negrini M. Lupini L, et al. Among authors: nemecek r. BMC Cancer. 2015 Oct 27;15:808. doi: 10.1186/s12885-015-1752-5. BMC Cancer. 2015. PMID: 26508446 Free PMC article.

2

MicroRNAs targeting EGFR signalling pathway in colorectal cancer.

Mlcochova J, Faltejskova P, Nemecek R, Svoboda M, Slaby O. Mlcochova J, et al. Among authors: nemecek r. J Cancer Res Clin Oncol. 2013 Oct;139(10):1615-24. doi: 10.1007/s00432-013-1470-9. Epub 2013 Jul 2. J Cancer Res Clin Oncol. 2013. PMID: 23817698 Review.

3

MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.

Mlcochova J, Faltejskova-Vychytilova P, Ferracin M, Zagatti B, Radova L, Svoboda M, Nemecek R, John S, Kiss I, Vyzula R, Negrini M, Slaby O. Mlcochova J, et al. Among authors: nemecek r. Oncotarget. 2015 Nov 17;6(36):38695-704. doi: 10.18632/oncotarget.5735. Oncotarget. 2015. PMID: 26497852 Free PMC article.

4

Mutational analysis of primary and metastatic colorectal cancer samples underlying the resistance to cetuximab-based therapy.

Nemecek R, Berkovcova J, Radova L, Kazda T, Mlcochova J, Vychytilova-Faltejskova P, Slaby O, Svoboda M. Nemecek R, et al. Onco Targets Ther. 2016 Jul 28;9:4695-703. doi: 10.2147/OTT.S102891. eCollection 2016. Onco Targets Ther. 2016. PMID: 27555788 Free PMC article.

5

[EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].

Svoboda M, Fabian P, Slabý O, Stanková M, Lakomý R, Nemecek R, Vyzula R. Svoboda M, et al. Among authors: nemecek r. Klin Onkol. 2010;23(4):224-30. Klin Onkol. 2010. PMID: 20806820 Review. Czech.

6

[Current Possibilities for Predicting Responses to EGFR Blockade in Metastatic Colorectal Cancer].

Němeček R, Svoboda M, Slabý O. Němeček R, et al. Klin Onkol. 2016;29(3):187-95. doi: 10.14735/amko2016187. Klin Onkol. 2016. PMID: 27296403 Review. Czech.

7

[Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].

Nēmecek R, Kocáková I, Kocák I, Svoboda M, Lakomý R, Poprach A, Vyskocil J, Vyzula R. Nēmecek R, et al. Klin Onkol. 2009;22(1):27-33. Klin Onkol. 2009. PMID: 19534437 Czech.

8

[Oncology in images: generalized Kaposi sarcoma].

Svoboda M, Grell P, Nemecek R, Sachlova M, Slampa P. Svoboda M, et al. Among authors: nemecek r. Klin Onkol. 2012;25(5):394. Klin Onkol. 2012. PMID: 23102203 Czech. No abstract available.

9

[Bevacizumab in combination with capecitabine and irinotecan (XELIRI) in treatment of metastatic colorectal cancer].

Kocáková I, Kocák I, Svoboda M, Nemecek R, Rehák Z, Standara M. Kocáková I, et al. Among authors: nemecek r. Klin Onkol. 2009;22(2):73-6. Klin Onkol. 2009. PMID: 19522377 Czech.

10

[The role of chemotherapy and targeted antiVEGF- and antiEGFR-therapy in metastatic colorectal cancer: a case report of long-term and intensive response].

Nemecek R, Vyzula R. Nemecek R, et al. Klin Onkol. 2011;24(6):465-9. Klin Onkol. 2011. PMID: 22257237 Czech.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

67 results

Search Page

Filters